|
1
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates, and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramakrishna R and Pisapia D: Recent
molecular advances in our understanding of glioma. Cureus.
7:e2872015.PubMed/NCBI
|
|
5
|
Fisher JL, Schwartzbaum JA, Wrensch M and
Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–90,
vii. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Hegi ME, van den Bent MJ, Mason
WP, Weller M, Mirimanoff RO and Cairncross JG; European
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups, ; National Cancer Institute of Canada Clinical
Trials Group, : Changing paradigms-an update on the
multidisciplinary management of malignant glioma. Oncologist.
11:165–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oermann E, Collins BT, Erickson KT, Yu X,
Lei S, Suy S, Hanscom HN, Kim J, Park HU, Eldabh A, et al:
CyberKnife® enhanced conventionally fractionated
chemoradiation for high grade glioma in close proximity to critical
structures. J Hematol Oncol. 3:222010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ottenhausen M, Krieg SM, Meyer B and
Ringel F: Functional preoperative and intraoperative mapping and
monitoring: Increasing safety and efficacy in glioma surgery.
Neurosurg Focus. 38:E32015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paw I, Carpenter RC, Watabe K, Debinski W
and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett.
362:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA. 105:pp.
10513–10518. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Babae N, Bourajjaj M, Liu Y, Van Beijnum
JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH,
Van Haastert RJ, et al: Systemic miRNA-7 delivery inhibits tumor
angiogenesis and growth in murine xenograft glioblastoma.
Oncotarget. 5:6687–6700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hwang H and Mendell J: microRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Frankel LB, Wen J, Lees M, Høyer-Hansen M,
Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent
inhibitor of autophagy. EMBO J. 30:4628–4641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Li Y and Lai M: The microRNA
network and tumor metastasis. Oncogene. 29:937–948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dontula R, Dinasarapu A, Chetty C, Pannuru
P, Herbert E, Ozer H and Lakka SS: microRNA 203 modulates glioma
cell migration via Robo1/ERK/MMP-9 signaling. Genes cancer.
4:285–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan
Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L and Luu HH:
Insulin-like growth factor (IGF) signaling in tumorigenesis and the
development of cancer drug resistance. Genes Dis. 2:13–25. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maris C, D'Haene N, Trépant AL, Le Mercier
M, Sauvage S, Allard J, Rorive S, Demetter P, Decaestecker C and
Salmon I: IGF-IR: A new prognostic biomarker for human
glioblastoma. Br J Cancer. 113:729–737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR and Freshney RI: Check your cultures! A list of
cross-contaminated or misidentified cell lines. Int J Cancer.
127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vermes I, Haanen C, Steffens-Nakken H and
Reutellingsperger C: A novel assay for apoptosis. Flow cytometric
detection of phosphatidylserine expression on early apoptotic cells
using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song B, Zhang C, Li G, Jin G and Liu C:
miR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan
S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the
proliferation, invasion, migration, and enhances the
chemosensitivity of non-small cell lung cancer cells by targeting
forkhead box A1 protein. Oncotarget. 7:13139–13152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Josephs DH, Bax HJ and Karagiannis SN:
Tumour-associated macrophage polarisation and re-education with
immunotherapy. Front Biosci (Elite Ed). 7:293–308. 2015.PubMed/NCBI
|
|
28
|
Seton-Rogers S: Tumour microenvironment:
Teaching old macrophages new tricks. Nat Rev Cancer. 13:7532013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ries CH, Cannarile MA, Hoves S, Benz J,
Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I,
et al: Targeting tumor-associated macrophages with anti-CSF-1R
antibody reveals a strategy for cancer therapy. Cancer Cell.
25:846–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tap WD, Wainberg ZA, Anthony SP, Ibrahim
PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro
GI, et al: Structure-guided blockade of CSF1R kinase in
tenosynovial giant-cell tumor. N Engl J Med. 373:428–437. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Quail DF, Bowman RL, Akkari L, Quick ML,
Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The
tumor microenvironment underlies acquired resistance to CSF-1R
inhibition in gliomas. Science. 352:aad30182016. View Article : Google Scholar : PubMed/NCBI
|
